Natco Pharma shares rise 2.5% as firm launches Semaglutide generic injection multi-dose vials in India

Natco Pharma shares rise 2.5% as firm launches Semaglutide generic injection multi-dose vials in India

• Natco launches Semaglutide vials in India after patent expiry
• Natco's vials are 70% cheaper than pen devices, boosting access
• Dr Reddy's and Emcure shares rise as Semaglutide patent expires

Did our AI summary help?

Shares of Natco Pharma were trading 2.5% higher on March 30 after the firm announced launch of Semaglutide Injection (multi-dose vials) in the India market tomorrow on Day 1 of patent expiry.

NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February 2026 for multi-dose vials and pen device based on the clinical comparison study.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

At 11:17 am on March 20, Natco Pharma shares were trading 2.6% higher at Rs 962.65 apiece.

Natco said it plans to launch Semaglutide injection in the form of multi-dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. Multi-dose vials will be launched at MRP of Rs 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of Rs 1,750 for 8mg/3ml.

Pen device will be priced at MRP of Rs 4,000, Rs 4,200 and Rs 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April 2026.

Natco said it is the first company to offer generic Semaglutide in multi dose vials with customised syringes. Natco is also offering the product to third parties for co-marketing.

"Natco is the first company to offer Semaglutide in the vial dosage form. It is the most affordable GLP-1 currently in the Indian market as it is approximately 70% cheaper in cost than the pen device and 90% cheaper than the price of the innovator’s brand. This will increase patient accessibility to the GLP-1 therapy and would help in long term compliance for the patients," said the company in a stock exchange filing.

Dr Reddy's Laboratories and Emcure Pharma are also in focus as Novo Nordisk's India patent on semaglutide expires today.

At 11:18 am on March 20, Dr Reddy's Laboratories shares were trading 1.5% higher while those of Emcure were trading 0.5% higher.